Consistently, our phase I clinical trial has also shown that intracoronary (IC) administration of autologous CD34+ cells significantly improved not only short-term [21] but also long-term [22] ischemia-related LV dysfunction as well as symptoms of angina and heart failure (HF). Here, CD34 is linked to hydrops fetalis.